Abstract
It is well known that glucocorticoids induce insulin resistance, but the exact time scale in humans is not well known. The aim of the study was to determine the time scale of effects of pharmacologic doses of glucocorticoids on insulin sensitivity. Subjects were treated with repeated methylprednisolone infusions and oral prednisone for Graves’ orbitopathy. Insulin sensitivity was determined using euglycemic hyper-insulinemic clamp (EHGC) before, during the first glucocorticoid infusion and after 2 months of treatment. EHGC started 2 h after the start of the glucocorticoid infusion, and lasted for 2 h. In another group of patients, insulin sensitivity was determined by short insulin tolerance test (SITT) before and during the first glucocorticoid infusion. SITT started 15 min after the start of the glucocorticoid infusion and lasted for 15 min. Ten subjects were included in each protocol. All were euthyroid during the study period. Four hours after the start of the glucocorticoid infusion significant reduction of insulin sensitivity was observed, which did not change for a further 2 months of glucocorticoid treatment [before 7.82 (95% confidence interval (CI) 5.35–10.29), first infusion, 4.93 (95% CI 2.99–6.87), after 2 months 5.36 (95%CI 3.91–6.81) mg/kg/min]. No significant change in insulin sensitivity occurred during the first 30 min of glucocorticoid infusion [before 139.7 (95%CI 94.1–185.3), during 146.7 (95%CI 106.3–187.1) μmol/l/min]. In humans, glucocorti-coid-induced insulin resistance develops quickly, in about 4 h, and does not change during further glucocorticoid treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obes Metab 2003, 5: 5–12.
Billaudel B, Sutter BC. Direct effect of corticosterone upon insulin secretion studied by three different techniques. Horm Metab Res 1979, 11: 555–60.
Billaudel B, Sutter BC. Immediate in-vivo effect of corticosterone on glucose-induced insulin secretion in the rat. J Endocrinol 1982, 95: 315–20.
Livingston JN, Lockwood DH. Effect of glucocorticoids on the glucose transport system of isolated fat cells. J Biol Chem 1975, 250: 8353–60.
Qi D, Pulinilkunnil T, An D, et al. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004, 53: 1790–7.
Perry CG, Spiers A, Cleland SJ, Lowe GD, Petrie JR, Connell JM. Glucocorticoids and insulin sensitivity: dissociation of insulin’s metabolic and vascular actions. J Clin Endocrinol Metab 2003, 88: 6008–14.
Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol 1998, 275: E806–13.
Tappy L, Randin D, Vollenweider P, et al. Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 1994, 79: 1063–9.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214–23.
Gelding SV, Robinson S, Lowe S, Niththyananthan R, Johnston DG. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol (Oxf) 1994, 40: 611–5.
R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing 2006.
Pinheiro JC, Bates DM. Mixed effects models in S and S-Plus. New York: Springer-Verlag New York 2000.
Rooney DP, Neely RD, Cullen C, et al. The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab 1993, 77: 1180–3.
Nicod N, Giusti V, Besse C, Tappy L. Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res 2003, 11: 625–31.
Besse C, Nicod N, Tappy L. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 2005, 13: 306–11.
Falkenstein E, Norman AW, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 2000, 85: 2072–5.
Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006, 246: 142–6.
Sutter-Dub MT. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 2002, 67: 77–93.
Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi MC, Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol Endocrinol Metab 2006, 291: E995–1002.
Asensio C, Muzzin P, Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obes Relat Metab Disord 2004, 28(Suppl 4): S45–52.
Fehm HL, Born J, Peters A. Glucocorticoids and melanocortins in the regulation of body weight in humans. Horm Metab Res 2004, 36: 360–4.
Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004, 145: 2633–8.
Epel E, Lapidus R, McEwen B, Brownell K. Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. Psychoneuroendocrinology 2001, 26: 37–49.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
>Zarković, M., Beleslin, B., Ćirić, J. et al. Glucocorticoid effect on insulin sensitivity: A time frame. J Endocrinol Invest 31, 238–242 (2008). https://doi.org/10.1007/BF03345596
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345596